CIK: 0001274403
Total reported value
$677.1M
Reporting period: 2026-03-31 · Number of holdings: 10
ARCH Venture Management, LLC disclosed 10 holdings in its latest 13F filing for the period ending 2026-03-31, with total reported value of $677.1M and a quarterly turnover rate of 38.4%.
Browse other institutions with $100M to $1B AUMBrowse other institutions starting with "A"
Sector classification currently covers about 0% of this portfolio's disclosed value; the remainder includes holdings (e.g. unmapped tickers, options, or other security types) not yet covered by our sector mapping.
Add ERAS
-35.9% $73.6M
Trim MAZE
0.0% -$47.7M
Add VIR
0.0% $37.8M
Trim GOSS
0.0% -$22.3M
Trim LYEL
+17.7% -$19.8M
Trim BEAM
0.0% -$17.7M
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | MAZE | Maze Therapeutics INC | Stock-Other | 18.16% | -8.03% | — | |
| 2 | RAPP | Rapport Therapeutics INC | Stock-Other | 17.23% | -0.13% | — | |
| 3 | VIR | Vir Biotechnology INC | Stock-Other | 17.09% | +5.14% | — | |
| 4 | ERAS | Erasca INC | Stock-Other | 16.95% | +10.64% | -35.86% | |
| 5 | BEAM | Beam Therapeutics INC | Stock-Other | 15.98% | -3.33% | — | |
| 6 | LYEL | Lyell Immunopharma INC | Stock-Other | 9.62% | -3.41% | +17.69% | |
| 7 | GENB | Generate Biomedicines INC | Stock-Other | 3.59% | +3.59% | NEW | |
| 8 | TXG | 10x Genomics Inc-class A | Stock-Other | 0.68% | -1.17% | -70.46% | |
| 9 | GOSS | Gossamer Bio INC | Stock-Other | 0.39% | -3.44% | — | |
| 10 | QTTB | Q32 Bio INC | Stock-Other | 0.30% | +0.14% | — |
Performance for Q3 2026
+8%
Performance Last 4 Quarters
+120.1%
Based on 82% of reported portfolio value with available pricing
Not enough sector-mapped data yet
| Period | Holdings | Total value | Stability | Top holdings |
|---|---|---|---|---|
| 2026-03-31 | 10 | $677.1M | 38 | |
| 2025-12-31 | 9 | $651.7M | 28 | |
| 2025-09-30 | 9 | $492.4M | 77 | |
| 2025-06-30 | 11 | $299.1M | 0 | |
| 2025-03-31 | 9 | $206.2M | 100 | |
| 2024-12-31 | 9 | $230.2M | 0 | |
| 2024-09-30 | 9 | $260.6M | 0 | |
| 2024-06-30 | 9 | $266.0M | 0 | |
| 2024-03-31 | 8 | $80.3M | 0 | |
| 2023-12-31 | 7 | $163.5M | 0 | |
| 2023-09-30 | 7 | $154.0M | 0 | |
| 2023-06-30 | 6 | $162.0M | 0 | |
| 2023-03-31 | 8 | $207.2M | 0 | |
| 2022-12-31 | 8 | $390.4M | 0 | |
| 2022-09-30 | 10 | $771.4M | 0 | |
| 2022-06-30 | 10 | $820.6M | 0 | |
| 2022-03-31 | 8 | $699.8M | 0 | |
| 2021-12-31 | 9 | $945.3M | 0 | |
| 2020-09-30 | 3 | $20.0M | 39 | |
| 2020-06-30 | 4 | $29.7M | 94 | |
| 2020-03-31 | 5 | $59.2M | 36 | |
| 2019-12-31 | 5 | $76.7M | 69 | |
| 2019-09-30 | 5 | $91.4M | 91 | |
| 2019-06-30 | 4 | $96.6M | 13 | |
| 2019-03-31 | 6 | $103.6M | 100 | |
| 2018-12-31 | 5 | $99.3M | 0 |
ARCH Venture Management, LLC's most significant position changes for 2026-03-31: New buy: Generate Biomedicines INC (GENB); Trim: Erasca INC (ERAS) — shares -35.86%; Add: Lyell Immunopharma INC (LYEL) — shares +17.69%; Trim: 10x Genomics Inc-class A (TXG) — shares -70.46%.
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | ERAS | Erasca INC | +10.6% | -35.86% | Trim |
| 2 | VIR | Vir Biotechnology INC | +5.1% | — | Unchanged |
| 3 | QTTB | Q32 Bio INC | +0.1% | — | Unchanged |
| 4 | RAPP | Rapport Therapeutics INC | -0.1% | — | Unchanged |
| 5 | TXG | 10x Genomics Inc-class A | -1.2% | -70.46% | Trim |
| 6 | BEAM | Beam Therapeutics INC | -3.3% | — | Unchanged |
| 7 | LYEL | Lyell Immunopharma INC | -3.4% | +17.69% | Add |
| 8 | GOSS | Gossamer Bio INC | -3.4% | — | Unchanged |
| 9 | MAZE | Maze Therapeutics INC | -8% | — | Unchanged |
| 10 | GENB | Generate Biomedicines INC | — | NEW | New buy |
| Period | Filed | Type | EDGAR |
|---|---|---|---|
| 2026-03-31 | 2026-05-15 | 13F-HR | View on EDGAR |
| 2025-12-31 | 2026-02-17 | 13F-HR | View on EDGAR |
| 2025-09-30 | 2025-11-14 | 13F-HR | View on EDGAR |
| 2025-06-30 | 2025-08-14 | 13F-HR | View on EDGAR |
| 2025-03-31 | 2025-05-15 | 13F-HR | View on EDGAR |
| 2024-12-31 | 2025-02-14 | 13F-HR | View on EDGAR |
| 2024-09-30 | 2024-11-14 | 13F-HR | View on EDGAR |
| 2024-06-30 | 2024-08-14 | 13F-HR | View on EDGAR |
| 2024-03-31 | 2024-05-15 | 13F-HR | View on EDGAR |
| 2023-12-31 | 2024-02-14 | 13F-HR | View on EDGAR |
| 2023-09-30 | 2023-11-14 | 13F-HR | View on EDGAR |
| 2023-06-30 | 2023-08-09 | 13F-HR | View on EDGAR |
| 2023-03-31 | 2023-05-15 | 13F-HR | View on EDGAR |
| 2022-12-31 | 2023-02-14 | 13F-HR | View on EDGAR |
| 2022-09-30 | 2022-11-10 | 13F-HR | View on EDGAR |
| 2022-06-30 | 2022-08-15 | 13F-HR | View on EDGAR |
| 2022-03-31 | 2022-05-27 | Amendment | View on EDGAR |
| 2022-03-31 | 2022-05-13 | 13F-HR | View on EDGAR |
| 2021-12-31 | 2022-02-14 | 13F-HR | View on EDGAR |
| 2020-09-30 | 2020-11-16 | 13F-HR | View on EDGAR |
| 2020-06-30 | 2020-08-12 | 13F-HR | View on EDGAR |
| 2020-03-31 | 2020-05-06 | 13F-HR | View on EDGAR |
| 2019-12-31 | 2020-02-05 | 13F-HR | View on EDGAR |
| 2019-09-30 | 2019-11-12 | 13F-HR | View on EDGAR |
| 2019-06-30 | 2019-08-09 | 13F-HR | View on EDGAR |
| 2019-03-31 | 2019-05-14 | 13F-HR | View on EDGAR |
| 2018-12-31 | 2019-05-17 | Amendment | View on EDGAR |
| 2018-12-31 | 2019-02-14 | 13F-HR | View on EDGAR |
Institutions with a similar AUM
CIK 0001307878
Total reported value
$677.2M
182 stks
2026-03-31
AUM within 0.0% of this institution
CIK 0001767750
Total reported value
$676.9M
13 stks
2026-03-31
AUM within 0.0% of this institution
CIK 0001865966
Total reported value
$676.7M
1,553 stks
2022-09-30
Stale — no recent filing
AUM within 0.1% of this institution
Institutions with overlapping top holdings
CIK 0001990717
Total reported value
$401.0M
3 stks
2026-03-31
2 of the top 5 holdings overlap, including Rapport Therapeutics INC
CIK 0000200406
Total reported value
$652.4M
16 stks
2026-03-31
1 of the top 5 holdings overlap, including Rapport Therapeutics INC
CIK 0001131399
Total reported value
$599.2M
13 stks
2026-03-31
1 of the top 5 holdings overlap, including Vir Biotechnology INC